Thr92Ala-DIO2 heterozygosity is associated with skeletal muscle mass and myosteatosis in patients with COVID-19
Authors' conclusion
Thr92Ala-DIO2 heterozygosity is associated with increased skeletal MA and less myosteatosis in patients with COVID-19. The protective effect of Thr92Ala-DIO2 heterozygosity on COVID-19 mortality is restricted to patients with reduced MA.
Study context
- Population
- Patients hospitalized with moderate-to-severe COVID-19 (June-August 2020), body composition assessed by non-contrast thoracic computed tomography (CT)
- Participants
- 181 consecutive patients
- Exposure
- Thr92Ala-DIO2 genotypes: Thr/Ala vs Thr/Thr vs Ala/Ala
- Thr/Thrn = 64
- Thr/Alan = 96
- Ala/Alan = 21
- Outcome
- Low muscle area (MA <92 cm²)
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
P = 0.027
- Prevalence of low muscle area (MA) (<92 cm²), all patients
- 52.5%
- Multivariate logistic regression (overdominant model): Thr/Ala associated with reduced risk of low MA vs Thr/Thr + Ala/Ala
- 41% to 69%
- Multivariate logistic regression (overdominant model): Thr/Ala associated with reduced risk of myosteatosis vs Thr/Thr + Ala/Ala
- 62% to 72%
Observational data: associations, not effects.
Further findings
- Kaplan-Meier: low muscle mass and homozygosity had lower survival rates than other groups
- Heterozygotes with MA ≥92 cm² had the best survival rate
Original publication
Thr92Ala-DIO2 heterozygosity is associated with skeletal muscle mass and myosteatosis in patients with COVID-19. Eur Thyroid J. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →